JNJ-61186372, JNJ-73841937, JNJ-61186372
61186372NSC3004
Phase 3 small_molecule active
Quick answer
JNJ-61186372, JNJ-73841937, JNJ-61186372 for EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active